Ciaffoni Joseph 4

What Happened

• Joseph Ciaffoni, Chief Executive Officer of Indivior Pharmaceuticals (INDV), received a grant of 79,976 restricted stock units (RSUs) on February 10, 2026. The RSUs were granted at $0.00 (no cash paid) and represent a contingent right to receive shares if vesting conditions are met. This is an award/grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-10; Filing date: 2026-02-12 (timely within the Form 4 two-business-day rule).
• Amount: 79,976 RSUs granted; reported acquisition price: $0.00 (grant).
• Vesting: RSUs vest in three equal annual installments beginning Feb 10, 2027, subject to continued service (see footnote F1).
• Shares owned after the transaction: Not specified in the filing.
• Footnotes/Exhibits: F1 describes RSU vesting schedule; Exhibit 24 is a Power of Attorney. No tax-withholding or sale-on-vesting details were disclosed in this filing.

Context

• RSU grants are a form of equity compensation that convert to ordinary shares only when they vest; they do not represent immediately tradable shares. Such awards are common for executive compensation and do not necessarily signal a near-term buy or sell by the insider.